Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)

0:00-18:08

ARDS, which is characterized by hypoxemic respiratory failure and inflammatory injury to the lungs, has a mortality rate of 30% to 40%. Balasubramanian Venkatesh, MD, of the George Institute for Global Health joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the effects of inhaled sedation with sevoflurane for patients with moderate to severe ARDS. Related Content: Sevoflurane Sedation in Acute Respiratory Distress Syndrome Inhaled Sedation in Acute Respiratory Distress Syndrome

Publisher

Healthy Dialogue

Link

edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2025.3350

Published

March 18, 2025

Duration

18 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

JAMA Network

HD

Healthy Dialogue

@healthydialogue

#inhaledsedation #sevoflurane #acuterespiratorydistress #medicine

The Nile